Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trilaciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 16/20 | 0.98 |
| ▸ | CDK6 known ✓ | Q00534 | 3/20 | 0.98 |
| ▸ | CDK2 | P24941 | 20/20 | 0.98 |
| ▸ | CCND1 | P24385 | 16/20 | 0.98 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.98 |
| ▸ | CCND3 | P30281 | 3/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.98 |
| ▸ | CDK9 | P50750 | 2/20 | 0.98 |
| ▸ | TTK | P33981 | 1/20 | 0.82 |
| ▸ | FLT3 | P36888 | 1/20 | 0.82 |
| ▸ | CCNH | P51946 | 1/20 | 0.82 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.82 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.82 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trilaciclib SCHEMBL29514690 | 1.00 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL10082028 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29763763 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29356370 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL4549924 | 0.98 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551643 | 0.92 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL10082029 | 0.92 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Lerociclib SCHEMBL23711495 | 0.91 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| Lerociclib SCHEMBL29409994 | 0.91 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| Lerociclib SCHEMBL29409995 | 0.91 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136610-A1 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-05-01 | — | — | US | claimed |
| EP-4486458-A1 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | Teva Pharmaceuticals International GmbH (CH) | 2025-01-08 | — | — | EP | claimed |
| WO-2024246723-A1 | SOLVATED FORM OF TRILACICLIB DIHYDROCHLORIDE | OLON S.P.A. (IT) | 2024-12-05 | — | — | WO | claimed |
| WO-2024241152-A1 | SOLVATED FORM OF TRILACICLIB DIHYDROCHLORIDE | OLON S.P.A. (IT) | 2024-11-28 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20230374028-A1 | SOLID STATE FORMS OF TRILACICLIB AND OF TRILACICLIB SALTS | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-11-23 | — | — | US | claimed |
| WO-2023164255-A1 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-08-31 | — | — | WO | claimed |
| WO-2022076779-A1 | SOLID STATE FORMS OF TRILACICLIB AND OF TRILACICLIB SALTS | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2022-04-14 | — | — | WO | claimed |
| WO-2026102147-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-122010959-A | Novel synthesis method of treasipril | 上海上药第一生化药业有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4730355-A1 | TYPING SYSTEM AND METHOD FOR HR-POSITIVE/HER2-NEGATIVE BREAST CANCER | Lumitype Medical (Huzhou) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-20260022132-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | TREELINE BIOSCIENCES INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260014272-A1 | GENERATION METHODS OF CHIMERIC ANTIGEN RECEPTOR ENGINEERED EXTRACELLULAR VESICLES | UNIV FLORIDA STATE RES FOUND INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2022125829-A1 | TREATMENTS FOR ADVANCED AND/OR METASTATIC TRIPLE NEGATIVE BREAST CANCER | G1 THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220175787-A1 | PATIENT SELECTION FOR ENHANCEMENT OF ANTI-TUMOR IMMUNITY IN CANCER PATIENTS | G1 THERAPEUTICS INC. (US) | 2022-06-09 | — | — | US | disclosed |
| WO-2022087018-A1 | IMPROVED FLUOROURACIL-BASED MULTI-AGENT CHEMOTHERAPY FOR TREATMENT OF METASTATIC COLORECTAL CANCER | G1 THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3986410-A1 | PATIENT SELECTION FOR ENHANCEMENT OF ANTI-TUMOR IMMUNITY IN CANCER PATIENTS | G1 Therapeutics, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022076779-A1 | SOLID STATE FORMS OF TRILACICLIB AND OF TRILACICLIB SALTS | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2022-04-14 | — | — | WO | disclosed |
| CN-114014864-A | Preparation process of traasiril compound | 武汉九州钰民医药科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014272-A1 | GENERATION METHODS OF CHIMERIC ANTIGEN RECEPTOR ENGINEERED EXTRACELLULAR VESICLES | CD274, PDCD1, PDCD1LG2 | CDK4 3226/4885CDK6 3097/4885CDK2 4408/4885 |
| US-20250136610-A1 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | ALK, BRAF, FLT3 | CDK4 85/4885CDK6 269/4885CDK2 166/4885 |
| US-20260022132-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | KRAS, NRAS, G3BP2 | CDK4 13/4885CDK6 48/4885CDK2 7/4885 |
| US-20230374028-A1 | SOLID STATE FORMS OF TRILACICLIB AND OF TRILACICLIB SALTS | BRAF, FLT3, KRAS | CDK4 8/4885CDK6 35/4885CDK2 15/4885 |
| US-20220175787-A1 | PATIENT SELECTION FOR ENHANCEMENT OF ANTI-TUMOR IMMUNITY IN CANCER PATIENTS | CDK4, CDK6, CDKL4 | CDK4 1/4885CDK6 2/4885CDK2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.